Doxorubicin Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Human Carbonyl Reductases (Cbr1 and Cbr3) in Southeast As

Total Page:16

File Type:pdf, Size:1020Kb

Doxorubicin Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Human Carbonyl Reductases (Cbr1 and Cbr3) in Southeast As View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by ScholarBank@NUS PHARMACODYNAMICS, PHARMACOKINETICS AND PHARMACOGENETICS OF DOXORUBICIN IN SINGAPOREAN BREAST CANCER PATIENTS Fan Lu A THESIS SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY DEPARTMENT OF PHARMACOLOGY NATIONAL UNIVERSITY OF SINGAPORE 2010 ACKNOWLEDGEMENTS I wish to express my thanks to my supervisors, Dr. Goh Boon Cher, Dr Lee Soo Chin and Associate Professor Lee How Sung, for providing me with the opportunity to pursue research in this field. I am grateful for their kind supports, guidance and scientific enthusiasm during my five years’ training. Through their patience and persistence, my postgraduate experience was immeasurably enriched. Special appreciation goes to Associate Professor Lee How Sung. She has always been ready with advice, encouragement and direction from the time I started to work with her in the Department of Pharmacology. I would like to thank Prof. Philip Moore for his support to my application for a part time study. I would like to acknowledge excellent advice and suggestions from my Ph.D. qualification examination committee members, A/Prof. Theresa, Tan May Chin, A/Prof. Paul Ho, and A/Prof. Boelsterli, Urs Alex. My thesis is the result of much more than individual effort. Thanks are also due to many scientific contributions and assistance of our many lab colleagues, collaborators, as well as friends. I would like to thank: Ms Khoo Yok Moi, Dr Wang Ling Zhi, Mr Guo Jia Yi, Ms Yap Hui Ling, Ms Jamsine Lim, Ms Norita Sukri and Dr Tham Lai Sam for sharing their knowledge, demonstrating bio-analytical techniques and providing their help and encouragement. I also would like to thank: Dr Rorbet Lim, Dr Ross Soo, Dr Yong Wei Peng, Dr Wong Chiung Ing, Dr Lim Siew Eng, Dr Benjamin Chuah and Dr Benjamin Mow from the National University Hospital, for I their kind help and advice in my whole study, especially in the preparation of presentation for American Society of Clinical Oncology annual meeting (2007). Last but not least, I would like to thank my family for their continued support and encouragement. II TABLE OF CONTENTS ACKNOWLEDGEMENTS I TABLE OF CONTENTS III SUMMARY VIII LIST OF TABLES XI LIST OF FIGURES XIII LIST OF ABBREVIATIONS XV LIST OF PUBLICATIONS AND PRESENTATIONS XVIII CHAPTER 1 INTRODUCTION 1 CHAPTER 2 LITERATURE REVIEW 9 2.1 Introduction of doxorubicin 10 2.2 Molecular structure of doxorubicin 10 2.3 Main mechanisms of anticancer cytotoxicity action 11 2.4 The clinical use of doxorubicin for breast cancer 16 2.4.1 Doxorubicin as a single agent for breast cancer 17 2.4.1.1 Efficacy of doxorubicin 17 2.4.1.2 Doxorubicin dose-response relationship 18 2.4.1.3 Dose limiting toxicities of doxorubicin 18 2.4.2 Chemotherapy with doxorubicin and docetaxel for breast cancer 20 2.5 Doxorubicin clinical pharmacokinetics 25 2.5.1 Distribution 25 2.5.2 Metabolism 27 2.5.2.1 Metabolic pathway of doxorubicin 27 2.5.2.2 Major metabolite of doxorubicinol 29 III 2.5.3 Elimination 31 2.6 Inter-patient variations in the PK and PD of doxorubicin 32 2.6.1 Inter-individual variations in PK 32 2.6.2 Inter-individual variations in PD 33 2.7 Reported PK-PD correlations 34 2.8 Inter-ethnic variations in the PD of doxorubicin 35 2.9 The pharmacogenetics of doxorubicin 36 2.9.1 The early studies on the pharmacogenetics of doxorubicin 36 2.9.2 Metabolism of doxorubicin to doxorubicinol 37 2.9.3 Human CBR1 substrates and CBR1 expression 41 2.9.4 Human CBR3 substrates and CBR3 expression 42 2.9.5 Functional alleles on human CBR1 and CBR3 43 2.9.6 Inter-ethnic variations of functional genetic variants on CBR1 46 and CBR3 2.10 Objectives 48 CHAPTER 3 MATERIAL AND METHODS 50 3.1 Clinical trial design and the patient recruitment 51 3.2 Efficacy and toxicity assessment 54 3.3 Chromatographic analysis of doxorubicin and doxorubicinol 57 3.3.1 Reagents and standards 57 3.3.2 Standard solutions, calibration and quality control samples 57 3.3.3 Sample collections and sample preparations 58 3.3.4 Chromatographic separation (HPLC) 59 3.3.5 Method validation 59 3.3.5.1 Chromatography 59 IV 3.3.5.2 Linearity 61 3.3.5.3 Precision and accuracy 63 3.3.5.4 Recovery 64 3.3.5.5 Stability 66 3.4 Pharmacokinetic analysis 69 3.5 Genetic variants on CBR1 and CBR3 71 3.5.1 Genomic DNA isolation 71 3.5.2 PCR amplification and purification 71 3.5.3 DNA sequencing 74 3.6 Cancer-free Asian subject population assay 75 3.7 Tumour tissue transcription analyses on CBR1 and CBR3 75 3.8 Statistical analysis 76 CHAPTER 4 RESULTS AND DISCUSSION 80 4.1 Patient characteristics 81 4.1.1 Characteristics of patients before the first cycle of doxorubicin 81 treatment 4.1.2 Comparison of patient characteristics between the two treatment 84 Arms 4.2 Efficacy 88 4.2.1 Anticancer efficacy 88 4.2.2 Comparison of patient’s anticancer efficacies between the two 89 treatment arms 4.2.3 Discussion 90 4.3 Toxicities 91 4.3.1 Hematologic toxicities 91 V 4.3.1.1 All patients’ hematologic toxicities 91 4.3.1.2 Comparison of patient’s hematologic toxicities between 92 two treatment arms 4.3.2 Non-hematological toxicities 94 4.3.3 Discussion 95 4.4 Clinical pharmacokinetics of doxorubicin 98 4.4.1 Comparison of pharmacokinetic parameters between the two 98 treatment arms 4.4.2 Clinical pharmacokinetics of doxorubicin 100 4.4.3 Discussion 102 4.5 Pharmacokinetic-pharmacodynamic relationships 104 4.5.1 Relationship of doxorubicin efficacy with PK 104 4.5.2 Relationship of hematologic toxicities with PK 108 4.5.3 Discussion 111 4.6 Doxorubicin pharmacogenetics on human CBR1 and CBR3 114 4.6.1 Human CBR1 and CBR3 genetic variants in Singaporean breast 114 cancer patients 4.6.1.1 Identified genetic variants on CBR1 and CBR3 114 4.6.1.2 Allelic frequencies of CBR1 and CBR3 genetic variants 118 4.6.1.3 Linkage disequilibrium 121 4.6.2 Influence of common CBR3 variants on the PK, PD of 122 doxorubicin and the tumour tissue CBR3 expression 4.6.2.1 CBR3 C4Y (11G>A) variant 122 4.6.2.1.1 PK correlations 122 4.6.2.1.2 Hematologic toxicity correlations 122 VI 4.6.2.1.3 Efficacy correlation 123 4.6.2.1.4 Tumour tissue CBR3 expression 123 4.6.2.2 CBR3 730G>A (V244M) variant 128 4.6.3 Influence of common CBR1 variants on the PK of doxorubicin 131 4.6.4 Correlation of leukocyte toxicity 132 4.6.5 Discussion 133 4.7 Inter-ethnic variations on the PD of doxorubicin 138 4.7.1 Inter-ethnic variations on hematologic toxicities 138 4.7.2 Inter-ethnic comparisons of CBR3 genotype 142 4.7.3 Genotype-phenotype correlation after stratifying for ethnicity 147 4.7.4 Discussion 151 CHAPTER 5 CONCLUSIONS 153 CHAPTER 6 FUTURE WORKS 160 REFERENCES 165 APPENDIX – Clinical trial protocol 176 VII SUMMARY Doxorubicin, as one of the most efficacious cytotoxic anticancer drugs, has been clinically used for more than thirty years. Despite its long history of use, the efficacy of treatment and the severity of myelosuppression after chemotherapy vary greatly from patient to patient, thus posing a major obstacle for clinical treatment of patients with doxorubicin. Understanding the sources of this pharmacodynamic variability, especially in terms of pharmacokinetic variability, potentially enhances the prospect of predicting toxicity, and individualising dosing for optimal outcome. Therefore, in the studies we have focused on investigation of the associations of the pharmacodynamics of doxorubicin (doxorubicin-induced hematologic toxicities and the tumour response) with the pharmacokinetic parameters and the genetic variants in CBR1 and CBR3 which encode the two main metabolizing enzymes that extensively reduce doxorubicin to doxorubicinol, the less hematologic and tumoural active metabolite. In this clinical study, ninety-nine female breast cancer patients (64 Chinese, 26 Malays, 7 Indians and 2 other ethnic origins) received the first-line doxorubicin at 75mg/m2 per dose every 3 weeks. Intra-tumoral CBR1 and CBR3 expressions had been investigated before the patients received chemotherapy. Pharmacokinetic data, toxicities, and tumour reductions were evaluated after the first cycle of doxorubicin treatment. Comprehensive sequencing of all coding regions, including the splice-site junctions of CBR1 and CBR3, was performed in the breast cancer patients. The allele frequencies of the important variants identified in the breast cancer patients were also examined in larger cancer-free Asian groups. VIII We found that the patient’s body surface area was not associated with the pharmacokinetics and pharmacodynamics of doxorubicin. However, the wide inter- patient variations observed in leukocyte suppression at nadir may be correlated with the plasma concentration ratios of doxorubicinol to doxorubicin at 1 hr after doxorubicin administration and the non-synonymous coding region variant in CBR3, C4Y (11G>A); whereas the doxorubicin-induced tumour reduction may be related to the pharmacokinetics parameter, K21, (the rate constant of peripheral tissue compartment to central blood compartment) and the genetic variant, CBR3, C4Y (11G>A). The most influential variant of CBR3 (11G>A) appeared to be associated with lower doxorubicinol AUC and lower doxorubicinol AUC/doxorubicin AUC metabolic ratios, suggesting that patients with the G allele may have greater catalytic conversion of doxorubicin to the less active metabolite, doxorubicinol. Consistently, patients with the G allele experienced significantly less leukocyte suppression at nadir and less tumour reduction.
Recommended publications
  • Steroid Recognition and Regulation of Hormone Action: Crystal
    Research Article 799 Steroid recognition and regulation of hormone action: crystal structure of testosterone and NADP+ bound to 3a-hydroxysteroid/ dihydrodiol dehydrogenase Melanie J Bennett1†, Ross H Albert1, Joseph M Jez1, Haiching Ma2, Trevor M Penning2 and Mitchell Lewis1* Background: Mammalian 3a-hydroxysteroid dehydrogenases (3a-HSDs) Addresses: 1Department of Biochemistry and modulate the activities of steroid hormones by reversibly reducing their C3 Biophysics, The Johnson Research Foundation, 37th and Hamilton Walk, Philadelphia, PA 19104- ketone groups. In steroid target tissues, 3a-HSDs act on 5a-dihydrotestosterone, 6059, USA and 2Department of Pharmacology, a potent male sex hormone (androgen) implicated in benign prostate hyperplasia University of Pennsylvania School of Medicine, 37th and prostate cancer. Rat liver 3a-HSD belongs to the aldo-keto reductase (AKR) and Hamilton Walk, Philadelphia, PA 19104-6084, superfamily and provides a model for mammalian 3a-, 17b- and 20a-HSDs, USA. which share > 65% sequence identity. The determination of the structure of 3a- †Present address: Division of Biology, California + HSD in complex with NADP and testosterone (a competitive inhibitor) will help Institute of Technology, 1200 E California Blvd., to further our understanding of steroid recognition and hormone regulation by Pasadena, CA 91125, USA. mammalian HSDs. *Corresponding author. E-mail: [email protected] Results: We have determined the 2.5 Å resolution crystal structure of recombinant rat liver 3a-HSD complexed with NADP+ and testosterone. The Key words: aldo-keto reductase, crystal structure, structure provides the first picture of an HSD ternary complex in the AKR 3a-hydroxysteroid/dihydrodiol dehydrogenase, superfamily, and is the only structure to date of testosterone bound to a protein.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Enzyme DHRS7
    Toward the identification of a function of the “orphan” enzyme DHRS7 Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Selene Araya, aus Lugano, Tessin Basel, 2018 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. Alex Odermatt (Fakultätsverantwortlicher) und Prof. Dr. Michael Arand (Korreferent) Basel, den 26.6.2018 ________________________ Dekan Prof. Dr. Martin Spiess I. List of Abbreviations 3α/βAdiol 3α/β-Androstanediol (5α-Androstane-3α/β,17β-diol) 3α/βHSD 3α/β-hydroxysteroid dehydrogenase 17β-HSD 17β-Hydroxysteroid Dehydrogenase 17αOHProg 17α-Hydroxyprogesterone 20α/βOHProg 20α/β-Hydroxyprogesterone 17α,20α/βdiOHProg 20α/βdihydroxyprogesterone ADT Androgen deprivation therapy ANOVA Analysis of variance AR Androgen Receptor AKR Aldo-Keto Reductase ATCC American Type Culture Collection CAM Cell Adhesion Molecule CYP Cytochrome P450 CBR1 Carbonyl reductase 1 CRPC Castration resistant prostate cancer Ct-value Cycle threshold-value DHRS7 (B/C) Dehydrogenase/Reductase Short Chain Dehydrogenase Family Member 7 (B/C) DHEA Dehydroepiandrosterone DHP Dehydroprogesterone DHT 5α-Dihydrotestosterone DMEM Dulbecco's Modified Eagle's Medium DMSO Dimethyl Sulfoxide DTT Dithiothreitol E1 Estrone E2 Estradiol ECM Extracellular Membrane EDTA Ethylenediaminetetraacetic acid EMT Epithelial-mesenchymal transition ER Endoplasmic Reticulum ERα/β Estrogen Receptor α/β FBS Fetal Bovine Serum 3 FDR False discovery rate FGF Fibroblast growth factor HEPES 4-(2-Hydroxyethyl)-1-Piperazineethanesulfonic Acid HMDB Human Metabolome Database HPLC High Performance Liquid Chromatography HSD Hydroxysteroid Dehydrogenase IC50 Half-Maximal Inhibitory Concentration LNCaP Lymph node carcinoma of the prostate mRNA Messenger Ribonucleic Acid n.d.
    [Show full text]
  • Apigenin-Loaded Solid Lipid Nanoparticle Attenuates Diabetic Nephropathy Induced by Streptozotocin Nicotinamide Through Nrf2/ HO-1/NF-Kb Signalling Pathway
    International Journal of Nanomedicine Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Apigenin-Loaded Solid Lipid Nanoparticle Attenuates Diabetic Nephropathy Induced by Streptozotocin Nicotinamide Through Nrf2/ HO-1/NF-kB Signalling Pathway This article was published in the following Dove Press journal: International Journal of Nanomedicine Pingping Li1 Background: Apigenin is known to have a broad-spectrum efficacy in oxidative stress and Syed Nasir Abbas Bukhari 2 conditions due to inflammation, although weak absorption, fast metabolic rate and a fast Tahseen Khan 3 elimination (systemic) limit the pharmacological efficacy of this drug. Hence, we propose the Renukaradhya Chitti4 usage of highly bioavailable Apigenin-solid lipid nanoparticles (SLNPs) to recognize such Davan B Bevoor5 limitations. The defensive function of Apigenin-SLNPs on renal damage induced by strep­ 6 tozotocin (STZ) in animals was studied. Anand R Hiremath −1 7 Materials and Methods: We initially injected the rats with 35 mg kg streptozocin intraper­ Nagaraja SreeHarsha −1 8 itoneally, and after 7 days, the rats were then injected 150 mg kg of metformin intragastrically Yogendra Singh followed by a once-daily intragastric dose of Apigenin-SLNP (25 or 50 mg kg−1) for 9 Kumar Shiva Gubbiyappa a continuous period of 30 days. We then measured the level of insulin and blood glucose, 1Department of Nephrology, Zhengzhou superoxide dismutase, catalase and malondialdehyde in the tissues of the kidney. We also Central Hospital Affiliated to Zhengzhou observed messenger-RNA expression of Interleukin-1β, Interleukin-6 and Tumor Necrosis University, Zhengzhou City, Henan Province 450007, People’s Republic of Factor-alpha in renal tissue through RT-PCR technique.
    [Show full text]
  • In Vivo Effect of Oracin on Doxorubicin Reduction, Biodistribution and Efficacy in Ehrlich Tumor Bearing Mice
    Pharmacological Reports Copyright © 2013 2013, 65, 445452 by Institute of Pharmacology ISSN 1734-1140 Polish Academy of Sciences Invivo effectoforacinondoxorubicinreduction, biodistributionandefficacyinEhrlichtumor bearingmice VeronikaHanušová1,PavelTomšík2,LenkaKriesfalusyová3, AlenaPakostová1,IvaBoušová1,LenkaSkálová1 1 DepartmentofBiochemicalSciences,CharlesUniversityinPrague,FacultyofPharmacy,Heyrovského1203, HradecKrálové,CZ-50005,CzechRepublic 2 DepartmentofMedicalBiochemistry,CharlesUniversityinPrague,FacultyofMedicine, Šimkova570, HradecKrálové,CZ-50038,CzechRepublic 3 Radio-IsotopeLaboratory,CharlesUniversityinPrague,FacultyofMedicine, Šimkova570,HradecKrálové, CZ-50038,CzechRepublic Correspondence: LenkaSkálová,e-mail:[email protected] Abstract: Background: The limitation of carbonyl reduction represents one possible way to increase the effectiveness of anthracycline doxo- rubicin (DOX) in cancer cells and decrease its toxicity in normal cells. In vitro, isoquinoline derivative oracin (ORC) inhibited DOX reduction and increased the antiproliferative effect of DOX in MCF-7 breast cancer cells. Moreover, ORC significantly decreases DOX toxicity in non-cancerous MCF-10A breast cells and in hepatocytes. The present study was designed to test in mice the in vivo effect of ORC on plasma and tissue concentrations of DOX and its main metabolite DOXOL. The effect of ORC on DOX efficacy in micebearingsolidEhrlichtumors(EST)wasalsostudied. Methods: DOX and DOX + ORC combinations were iv administered to healthy mice. Blood samples, livers
    [Show full text]
  • Reactive Carbonyls and Oxidative Stress: Potential for Therapeutic Intervention ⁎ Elizabeth M
    Pharmacology & Therapeutics 115 (2007) 13–24 www.elsevier.com/locate/pharmthera Associate editor: R.M. Wadsworth Reactive carbonyls and oxidative stress: Potential for therapeutic intervention ⁎ Elizabeth M. Ellis Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 204 George Street, Glasgow, G1 1XW, United Kingdom Abstract Reactive aldehydes and ketones are produced as a result of oxidative stress in several disease processes. Considerable evidence is now accumulating that these reactive carbonyl products are also involved in the progression of diseases, including neurodegenerative disorders, diabetes, atherosclerosis, diabetic complications, reperfusion after ischemic injury, hypertension, and inflammation. To counter carbonyl stress, cells possess enzymes that can decrease aldehyde load. These enzymes include aldehyde dehydrogenases (ALDH), aldo-keto reductases (AKR), carbonyl reductase (CBR), and glutathione S-transferases (GST). Some of these enzymes are inducible by chemoprotective compounds via Nrf2/ ARE- or AhR/XRE-dependent mechanisms. This review describes the metabolism of reactive carbonyls and discusses the potential for manipulating levels of carbonyl-metabolizing enzymes through chemical intervention. © 2007 Elsevier Inc. All rights reserved. Keywords: Aldehyde metabolism; Oxidative stress; Chemoprotection Contents 1. Introduction ............................................. 14 2. Production of reactive carbonyls in oxidant-exposed cells . .................... 14 2.1. Carbonyls produced
    [Show full text]
  • Men's Health& Testosterone
    Q&A: NEW ENDOCRINE REVIEWS EIC DANIEL J. DRUCKER, MD JUNE 2018 THE LEADING MAGAZINE FOR ENDOCRINOLOGISTS Men’s Health & Testosterone ● New Endocrine Society guidelines detail why hypogonadism patients should be treated when consistently low T levels are tied to symptoms, not what the patient saw on television. ● A closer look at the T Trials shows that testosterone therapy may actually be suitable for older patients with hypogonadism. ONCE A DAY: ENS New research may finally achieve the “male pill” M ’ WHY ENDOCRINOLOGY?: A newcomer’s perspective from the bench HEALTH & TESTOSTERONE TEST YOUR KNOWLEDGE WITH PEDIATRIC ESAPTM THE LEADING MAGAZINE FOR ENDOCRINOLOGISTS 2017-2018 2017 – 2019 EDITORIAL ADVISORY BOARD Henry Anhalt, DO Bergen County Pediatric Endocrinology Chair, Hormone Health Network VP, Medical Affairs, Science 37 Sally Camper, PhD Department of Human Genetics University of Michigan Medical School Rodolfo J. Galindo, MD Assistant Professor of Medicine Mount Sinai School of Medicine Christian M. Girgis, MBBS, PhD, FRACP Royal North Shore and Westmead Hospitals University of Sydney, Australia Andrea Gore, PhD Division of Pharmacology and Toxicology University of Texas Daniel A. Gorelick, PhD Solve 100 New Cases In Department of Pharmacology & Toxicology University of Alabama at Birmingham One Module, Now Delivering: M. Carol Greenlee, MD, FACP Interactive online modules Western Slope Endocrinology Grand Junction, Colo. and printed reference book (Faculty for Transforming Clinical Practice initiative [TCPi]) Peer-review comparisons Gary D. Hammer, MD, PhD for each question Millie Schembechler Professor of Adrenal Cancer, Endocrine Oncology Program Detailed overall University of Michigan performance report Robert W. Lash, MD Chief Professional & Clinical Officer, Endocrine Society Lab values in conventional and SI Units Karl Nadolsky, DO Diabetes Obesity & Metabolic Institute 40 ABP MOC Part 2 points and Walter Reed National Military Medical Center; Uniformed Services University 40.0 AMA PRA Category 1 Credits™ Joshua D.
    [Show full text]
  • Flavonoid Apigenin Is an Inhibitor of the NAD+Ase CD38: Implications for Cellular NAD+ Metabolism, Protein Acetylation, and Treatment of Metabolic Syndrome
    Flavonoid Apigenin Is an Inhibitor of the NAD+ase CD38: Implications for Cellular NAD+ Metabolism, Protein Acetylation, and Treatment of Metabolic Syndrome The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Escande, Carlos, Veronica Nin, Nathan L. Price, Verena Capellini, Ana P. Gomes, Maria Thereza Barbosa, Luke O’Neil, Thomas A. White, David A. Sinclair, and Eduardo N. Chini. 2013. “Flavonoid Apigenin Is an Inhibitor of the NAD+ase CD38: Implications for Cellular NAD+ Metabolism, Protein Acetylation, and Treatment of Metabolic Syndrome.” Diabetes 62 (4): 1084-1093. doi:10.2337/ db12-1139. http://dx.doi.org/10.2337/db12-1139. Published Version doi:10.2337/db12-1139 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12152908 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA ORIGINAL ARTICLE Flavonoid Apigenin Is an Inhibitor of the NAD+ase CD38 Implications for Cellular NAD+ Metabolism, Protein Acetylation, and Treatment of Metabolic Syndrome Carlos Escande,1 Veronica Nin,1 Nathan L. Price,2 Verena Capellini,1 Ana P. Gomes,2 Maria Thereza Barbosa,1 Luke O’Neil,1 Thomas A. White,1 David A. Sinclair,2 and Eduardo N. Chini1 Metabolic syndrome is a growing health problem worldwide. It is syndrome (5). This concept was later expanded by others therefore imperative to develop new strategies to treat this using different approaches, including inhibition of poly-ADP- + pathology.
    [Show full text]
  • Zambia Essential Medicine List (Zeml) 03 2013
    ZAMBIA ESSENTIAL MEDICINE LIST (ZEML) 03 2013 Drug Presentation Level VEN 1 Drugs used in anaesthesia 1.1. Drugs used in general anaesthesia 1.1.1 Intravenous and intramuscular anaesthetics 1.1.1.1 Ketamin injection 10mg/ml (10 ml) II-IV V 1.1.1.2 Thiopentone sodium powder for reconstitution 1g and 5g vials II-IV V 1.1.2 Inhalation anaesthetics 1.1.2.1 Halothane inhalation II-IV V 1.1.2.2 Nitrous oxide medical gas II-IV E 1.1.3 Muscle relaxants 1.1.3.1 Suxamethonium chloride injection 50mg/ml, (2ml) II-IV V 1.1.4 Anticholinesterases 1.1.4.1 Neostigmine injection 2.5mg/ml, (1ml) II-IV V 1.2 Drugs used in local anaesthesia 1.2.1. Lignocaine injection 1% (10ml, 50ml) I-IV V 1.2.2 Lignocaine + adrenaline dental cartridge injection 2% (1 in 80,000) II-IV V 1.3 Drugs used in spinal anaesthesia 1.3.1 Bupivacaine/glucose injection 0.5%, (4ml) IV E 1 Drug Presentation Level VEN 2. Drugs acting on the gastrointestinal system 2.1 Antacids 2.1.1 Aluminium hydroxide gel, chewable tablets I-IV E 2.12 Magnesium trisilicate Compound chewable tablets, mixture I-IV E 2.2. Antispasmodics 2.2.1 Hyoscine butyl bromide injection 20mg/ml, (1ml) II-IV E 2.2.2 Propantheline bromide tablets 15mg I-IV E 2.3 Ulcer healing drugs 2.3.1 Cimetidine tablets 200mg II-IV E 2.3.2 Omeprazole tablets 10mg, II-IV E 2.3.3 Ranitidine tablets 150mg II-IV E 2.3.4 Tripotassium dicitratobismuthate tablets 120mg II-IV E 2.3.5 Clarithromycin tablets 250mg II-IV E 2.4.
    [Show full text]
  • Biochemical and Pharmacological Characterization of Cytochrome B5 Reductase As a Potential Novel Therapeutic Target in Candida A
    University of South Florida Scholar Commons Graduate Theses and Dissertations Graduate School January 2011 Biochemical and Pharmacological Characterization of Cytochrome b5 Reductase as a Potential Novel Therapeutic Target in Candida albicans Mary Jolene Patricia Holloway University of South Florida, [email protected] Follow this and additional works at: http://scholarcommons.usf.edu/etd Part of the American Studies Commons, Biochemistry Commons, Microbiology Commons, and the Molecular Biology Commons Scholar Commons Citation Holloway, Mary Jolene Patricia, "Biochemical and Pharmacological Characterization of Cytochrome b5 Reductase as a Potential Novel Therapeutic Target in Candida albicans" (2011). Graduate Theses and Dissertations. http://scholarcommons.usf.edu/etd/3730 This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact [email protected]. Biochemical and Pharmacological Characterization of Cytochrome b5 Reductase as a Potential Novel Therapeutic Target in Candida albicans by Mary Jolene Holloway A dissertation written in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Molecular Medicine College of Medicine University of South Florida Major Professor: Andreas Seyfang, Ph.D. Co-Major Professor: Robert Deschenes, Ph.D. Michael J. Barber, D.Phil Gloria Ferreira, Ph.D. Alberto van Olphen, Ph.D. Date of Approval: November 14, 2011 Keywords: Fungal drug resistance, protein biochemistry and structure, ergosterol biosynthesis, yeast knockouts, oxidoreductases Copyright © 2011, Mary Jolene Holloway i DEDICATION This work is dedicated to my mother, Theresa Holloway, for being my coach and friend.
    [Show full text]
  • Anti-Oxidant Pathogenesis of High-Grade Glioma DISSERTATION
    Anti-Oxidant Pathogenesis of High-Grade Glioma DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Ji Eun Song, M.S. Graduate Program in Molecular, Cellular and Developmental Biology The Ohio State University 2015 Dissertation Committee: Dr. Chang-Hyuk Kwon, Advisor Dr. Balveen Kaur, Co-advisor Dr. Vincenzo Coppola Dr. Thomas Ludwig Copyright by Ji Eun Song 2015 Abstract High-grade glioma (HGG) is the most aggressive primary brain malignancies, and is incurable despite the best combination of current cancer therapies. A median patient survival of glioblastoma (GBM, the most aggressive grade 4 glioma) is only 14.6 months (Stupp et al., 2005). Therefore, innovative and more effective therapy for HGG is urgently needed. It has been known that dysregulated reactive oxygen species (ROS) signaling is associated with many human diseases, including cancers. Oxidative stress by excessive accumulation of ROS has been known to promote carcinogenesis through both genetic and epigenetic modifications (Ziech, Franco, Pappa, & Panayiotidis, 2011). Expressions of anti-oxidant proteins are reportedly increased by ROS- induced oxidative stress (Polytarchou, Pfau, Hatziapostolou, & Tsichlis, 2008). Because excessive oxidative stress can cause cellular senescence and apoptosis, it appears that tumor cells overexpress anti-oxidant proteins as a defense mechanism against elevated ROS. Therefore, targeting a predominant anti-oxidant protein could be an effective strategy for treating tumors. Peroxiredoxin 4 (PRDX4) is an ROS-scavenging enzyme and facilitates proper protein folding in the endoplasmic reticulum (ER). We reported that PRDX4 levels ii were highly increased in a majority of human HGGs as well as in a mouse model of HGG.
    [Show full text]
  • Chromosome 21 Leading Edge Gene Set
    Chromosome 21 Leading Edge Gene Set Genes from chr21q22 that are part of the GSEA leading edge set identifying differences between trisomic and euploid samples. Multiple probe set IDs corresponding to a single gene symbol are combined as part of the GSEA analysis. Gene Symbol Probe Set IDs Gene Title 203865_s_at, 207999_s_at, 209979_at, adenosine deaminase, RNA-specific, B1 ADARB1 234539_at, 234799_at (RED1 homolog rat) UDP-Gal:betaGlcNAc beta 1,3- B3GALT5 206947_at galactosyltransferase, polypeptide 5 BACE2 217867_x_at, 222446_s_at beta-site APP-cleaving enzyme 2 1553227_s_at, 214820_at, 219280_at, 225446_at, 231860_at, 231960_at, bromodomain and WD repeat domain BRWD1 244622_at containing 1 C21orf121 240809_at chromosome 21 open reading frame 121 C21orf130 240068_at chromosome 21 open reading frame 130 C21orf22 1560881_a_at chromosome 21 open reading frame 22 C21orf29 1552570_at, 1555048_at_at, 1555049_at chromosome 21 open reading frame 29 C21orf33 202217_at, 210667_s_at chromosome 21 open reading frame 33 C21orf45 219004_s_at, 228597_at, 229671_s_at chromosome 21 open reading frame 45 C21orf51 1554430_at, 1554432_x_at, 228239_at chromosome 21 open reading frame 51 C21orf56 223360_at chromosome 21 open reading frame 56 C21orf59 218123_at, 244369_at chromosome 21 open reading frame 59 C21orf66 1555125_at, 218515_at, 221158_at chromosome 21 open reading frame 66 C21orf7 221211_s_at chromosome 21 open reading frame 7 C21orf77 220826_at chromosome 21 open reading frame 77 C21orf84 239968_at, 240589_at chromosome 21 open reading frame 84
    [Show full text]